Reduction in mouse allergen exposure is associated with greater lung function growth - 05/02/20
Abstract |
Background |
Current childhood asthma therapies have little effect on lung function trajectory.
Objective |
We sought to determine whether mouse allergen exposure reduction is associated with lung function growth in mouse-sensitized/exposed asthmatic children.
Methods |
Three hundred fifty mouse-sensitized/exposed asthmatic children (5-17 years old) were enrolled in a 1-year randomized trial of integrated pest management plus education versus education alone. Prebronchodilator/postbronchodilator spirometry was performed at baseline and 6 and 12 months, and bedroom floor mouse allergen levels were measured every 3 months. Mouse allergen reduction was defined as a 75% or greater decrease in mouse allergen levels from baseline. Treatment groups were combined for analyses because there were no differences in outcomes between groups. Changes in lung function over time were modeled, adjusting for age, sex, race, atopy, group, and bronchodilator reversibility and including an interaction term (allergen reduction*time).
Results |
The study population was predominantly black (79.4%) and low income (66.3% [<$30,000]). At baseline, the median mouse allergen level was 5.7 μg/g (interquartile range, 1.5-22.8 μg/g), and the mean (SD) prebronchodilator FEV1/forced vital capacity ratio was 80.2% (9.0%). Ninety-two (26.3%) participants had 75% or greater reduction in mouse allergen levels. For a 10-year-old black boy, 75% or greater allergen reduction was associated with an increase in prebronchodilator FEV1 of 238 mL/y (95% CI, 177-299 mL/y), whereas less than 75% allergen reduction was associated with an increase in prebronchodilator FEV1 of 131 mL/y (95% CI, 97-166 mL/y). Estimated differences in prebronchodilator and postbronchodilator FEV1 growth were as follows: 107 mL/y (95% CI, 37-177 mL/y; Pint = .003) and 48 mL/y (95% CI, −17 to 113 mL/y; Pint = .15), respectively. Estimated differences in prebronchodilator and postbronchodilator forced expiratory flow at 25% to 75% of vital capacity growth were as follows: 182 mL/y (95% CI, 61-304 mL/y; Pint = .003) and 181 mL/y (95% CI, 48-314 mL/y; Pint = .008), respectively.
Conclusion |
Mouse allergen reduction is associated with greater increases in prebronchodilator FEV1 and prebronchodilator/postbronchodilator forced expiratory flow at 25% to 75% of vital capacity over 1 year among sensitized/exposed asthmatic children.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Key words : Allergen exposure, allergen exposure reduction, lung function growth, lung function trajectory, mouse allergen exposure, allergen-sensitized and exposed asthmatic children, allergic asthma
Abbreviations used : COPD, FEF25-75, FVC, ICS, MAAIT, SPT
Plan
| Supported by National Institutes of Health grants U01 Al 083238, K24 AI 106822, K24 AI114769 R01 ES023447, P50ES015903, and P01 ES018176. |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
|
| This study is registered under NCT01251224 at clinicaltrials.gov. |
Vol 145 - N° 2
P. 646 - février 2020 Retour au numéro
Article précédent
- Activated NLR family pyrin domain containing 3 (NLRP3) inflammasome in keratinocytes promotes cutaneous T-cell response in patients with vitiligo
- Shuli Li, Pan Kang, Weigang Zhang, Zhe Jian, Qian Zhang, Xiuli Yi, Sen Guo, Weinan Guo, Qiong Shi, Bing Li, Yuanmin He, Pu Song, Ling Liu, Kai Li, Gang Wang, Tianwen Gao, Chunying Li
- Peptides from allergenic lipocalins bind to formyl peptide receptor 3 in human dendritic cells to mediate TH2 immunity
- Dominik Klaver, Beate Posch, Anita Geisler, Martin Hermann, Norbert Reider, Christine Heufler
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?